AZNAstraZenecaRunning, no new patients
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
Stage IB-IIIA Non-small Cell Lung Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 682 (final count)
- Started
- Oct 21, 2015
- Main results expected
- Apr 11, 2022
- Fully finished
- Jan 31, 2029
- Results posted
- Jul 27, 2021
What counts as success
The trial's main goal(s), called the “primary outcome.”
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).
Measured over: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02511106 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC